Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 5/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.41 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881928 | 0.89 | CRHR1 (0.54) | CRHR1SCN9ATXNRD1EIF4ERUNX1 | |
| SCHEMBL4628330 | 0.88 | CRHR1 (0.43) | CRHR1SCN9ATXNRD1EIF4ERUNX1 | |
| SCHEMBL4628316 | 0.88 | CRHR1 (0.43) | CRHR1SCN9ATXNRD1EIF4ERUNX1 | |
| SCHEMBL4628946 | 0.85 | CRHR1 (0.41) | CRHR1SCN9ATXNRD1EIF4ERUNX1 | |
| SCHEMBL4878756 | 0.81 | CRHR1 (0.55) | CRHR1SCN9ARUNX1GPR3SCN5A | |
| SCHEMBL6343330 | 0.79 | SCN9A (0.43) | CRHR1SCN9ARUNX1GPR3MEN1 | |
| SCHEMBL14183023 | 0.79 | CRHR1 (0.49) | CRHR1SCN9ATXNRD1RUNX1GPR3 | |
| SCHEMBL6343532 | 0.78 | CRHR1 (0.55) | CRHR1SCN9ARUNX1GPR3 | |
| SCHEMBL4882896 | 0.75 | CRHR1 (0.60) | CRHR1SCN9A | |
| SCHEMBL4626672 | 0.75 | CRHR1 (0.48) | CRHR1SCN9ARUNX1GPR3SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176721-A1 | 2,5-Diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylprimidines | HUANG JIANHUA (US) | 2005-08-11 | — | — | US | disclosed |
| US-6887875-B2 | Bind with high selectivity and/ or high affinity to CRF1 receptors (Corticotropin Releasing Factor 1 Receptors), useful for treating psychiatric and neurological diseases, including depression, anxiety and post trauma stress | NEUROGEN CORPORATION (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1399428-A1 | 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030119844-A1 | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines | NEUROGEN CORPORATION | 2003-06-26 | — | — | US | disclosed |
| WO-2002100838-A1 | 2,5-DIARYLPYRAZINES, 2,5-DIARYLPYRIDINES AND 2,5-DIARYLPYRIMIDINES AS CRF1 RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119844-A1 | 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines | CRHR2, CRHR1, CRH | CRHR1 2/4885SCN9A 4209/4885TXNRD1 616/4885 |
| US-20050176721-A1 | 2,5-Diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylprimidines | CRHR2, CRHR1, CRH | CRHR1 2/4885SCN9A 4071/4885TXNRD1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.